Majidinia Maryam, Yousefi Bahman
Department of Clinical Biochemistry, Faculty of Medicine, Urmia University Medical Sciences, Urmia, Iran.
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Chem Biol Drug Des. 2017 Mar;89(3):309-318. doi: 10.1111/cbdd.12893. Epub 2017 Jan 2.
Breast cancer is the most common cancer and the second leading cause of cancer-related death in women worldwide. In spite of huge advancements in early detection and ever-increasing knowledge of breast cancer biology, approximately 30% of patients with early-stage breast cancer experience disease recurrence. Most patients are chemosensitive and cancer free immediately after the treatment. About 50% to 70% of breast cancer patients, however, will relapse within 1 year. Such a relapse is usually concomitant with adenocarcinoma cells acquiring a chemoresistant phenotype. Both de novo and acquired chemoresistance are poorly understood and present a major burden in the treatment of breast cancer. Although, previously, chemoresistance was largely linked to genetic alterations within the cancer cells, recent investigations are indicating that chemoresistance can also be associated with the tumor microenvironment. Nowadays, it is widely believed that tumor microenvironment is a key player in tumor progression and response to treatment. In this study, we will review the interactions of breast tumor cells with their microenvironment, present the latest research on the resistance mediated by the stromal component in breast cancer, and discuss the potential therapeutic strategies that can be exploited to treat breast cancers by targeting tumor microenvironment.
乳腺癌是全球女性中最常见的癌症，也是癌症相关死亡的第二大主要原因。尽管在早期检测方面取得了巨大进展，并且对乳腺癌生物学的了解也不断增加，但仍有大约30%的早期乳腺癌患者会出现疾病复发。大多数患者在治疗后对化疗敏感且无癌。然而，约50%至70%的乳腺癌患者会在1年内复发。这种复发通常伴随着腺癌细胞获得化疗耐药表型。原发性和获得性化疗耐药都了解甚少，并且是乳腺癌治疗中的一个主要负担。虽然以前化疗耐药在很大程度上与癌细胞内的基因改变有关，但最近的研究表明，化疗耐药也可能与肿瘤微环境有关。如今，人们普遍认为肿瘤微环境是肿瘤进展和对治疗反应的关键因素。在本研究中，我们将综述乳腺肿瘤细胞与其微环境的相互作用，介绍乳腺癌中由基质成分介导的耐药性的最新研究，并讨论通过靶向肿瘤微环境可用于治疗乳腺癌的潜在治疗策略。
